Enkephinex-OA 99% Enkephalinase Inhibitor (ENKi)

Enkephinex-OA is an enkephalinase inhibitor with modest oral potency and efficacious BBB penetration.  An analogue of RB-120 it demonstrates robust efficacy within in vivo models for analgesic, antidepressant, and anxiolytic paradigms.

Animal Model Pharmacokinetics:

Animal model (mice) pharmacokinetic studies demonstrates strong BBB penetration with very modest oral bioavailability.

Half-Life:  Approximately 3.8 hours

Potential Human Use Protocols and Projections:

Within extrapolations from in vivo animal models projected dose arms for clinical trial are at 250mg, 500mg, and 1000mg b.i.d. that would be applicable for antidepressant and analgesic/analgesic-sparing trials.  Addiction cessation is another potential target goal.

Though Enkephinex-OA demonstrates some modest oral bioavailability efficacy would appear to be far superior within sublingual administration.  Efficacious dosages for sublingual administration are projected at 15mg to 60mg.

Format of Supply:  60mg/ml in ethanol

USAGE: For Research Use Only! Not For Use in Humans.